99 related articles for article (PubMed ID: 6376892)
1. [Effect of urokinase therapy in patients with glomerulonephritis and nephrotic syndrome. Trial at multiple institutes in Japan].
Tomura S; Takeuchi J; Tanaka K
Nihon Jinzo Gakkai Shi; 1984 Jan; 26(1):97-121. PubMed ID: 6376892
[No Abstract] [Full Text] [Related]
2. [A study on the urokinase treatment in patients with glomerulonephritis and nephrotic syndrome].
Konishi K; Kato E; Iyori S; Higashi F
Nihon Jinzo Gakkai Shi; 1982 Apr; 24(4):429-44. PubMed ID: 6750187
[No Abstract] [Full Text] [Related]
3. [Studies on the fibrinolytic therapy in patients with various renal diseases. Clinical effects of urokinase (author's transl)].
Takasaki H; Shibata M
Nihon Jinzo Gakkai Shi; 1981 Sep; 23(9):1271-80. PubMed ID: 7035725
[No Abstract] [Full Text] [Related]
4. [A study of fibrinolytic therapy in glomerulonephritis and nephrotic syndrome. III. Indication, time to start therapy and criteria of effect (author's transl)].
Sato M; Nakazora H; Ohfuji T
Nihon Jinzo Gakkai Shi; 1977 Sep; 19(9):717-31. PubMed ID: 599731
[No Abstract] [Full Text] [Related]
5. [Fibrinolytic system in patients with nephrotic syndrome].
Andreenko GV; Poliantseva LR; Smirnova TA; Podorol'skaia LV
Ter Arkh; 1976; 40(2):89-99. PubMed ID: 135367
[No Abstract] [Full Text] [Related]
6. [Intraglomerular coagulation and fibrinolysis in human primary glomerular diseases].
Shibata K; Dohi K; Fujii Y; Ishikawa H
Nihon Jinzo Gakkai Shi; 1991 Aug; 33(8):719-29. PubMed ID: 1770632
[TBL] [Abstract][Full Text] [Related]
7. [The fibrinolytic therapy in renal disease (author's transl)].
Kaburagi T; Yokoyama S; Tanaka K; Haniu T; Suzuki T; Mithunami K; Takayama S; Oguma S; Hatori T; Kishimoto T; Tomimoto K
Nihon Jinzo Gakkai Shi; 1980 Jan; 22(1):59-79. PubMed ID: 6991744
[No Abstract] [Full Text] [Related]
8. Clinical effect of urokinase on chronic glomerulonephritis (group study).
Abe T
New Istanbul Contrib Clin Sci; 1978 Mar; 12(2):123-32. PubMed ID: 16302698
[No Abstract] [Full Text] [Related]
9. [Primary nephrotic syndrome treated with urokinase--a report of 20 cases].
Wang LS; Chen EH; Zhou XJ
Zhonghua Nei Ke Za Zhi; 1989 Jun; 28(6):356-9, 382. PubMed ID: 2582915
[TBL] [Abstract][Full Text] [Related]
10. [On coagulation and fibrinolysis in renal diseases, with special reference to FDP subfragment and urinary plasmin body].
Nakamichi S
Nihon Jinzo Gakkai Shi; 1984 Apr; 26(4):353-66. PubMed ID: 6236317
[No Abstract] [Full Text] [Related]
11. [Clinical importance of determination of the products of decomposition of fibrin and fibrinogen in urine in patients with glomerulonephritis].
Belitskaia GA; Ena IaM; Varetskaia TV; Tsynkalevskaia SN; Tsariuk LA
Ter Arkh; 1975; 47(4):46-50. PubMed ID: 1145480
[No Abstract] [Full Text] [Related]
12. Fibrinogen-fibrin degradation products in renal disorders.
Dube B; Srivastava PK; Padmanabhan R; Dube RK
Indian J Pathol Microbiol; 1979 Oct; 22(4):313-22. PubMed ID: 548482
[No Abstract] [Full Text] [Related]
13. [Blood coagulation system and fibrinolysis in glomerulonephritis (review of the literature)].
Panchenko VM; Gilunova NI; Kozhomkulova BZh
Lab Delo; 1977; (8):451-4. PubMed ID: 72846
[No Abstract] [Full Text] [Related]
14. [The levels of fibrinopeptide A and fibrinopeptide B beta in the urine from patients with chronic glomerulonephritis during urokinase therapy].
Miura M; Tomino Y; Inoue W; Tamura S; Nomoto Y; Sakai H; Itoh K
Rinsho Byori; 1985 Jun; 33(6):652-6. PubMed ID: 4032804
[No Abstract] [Full Text] [Related]
15. [Significance of urinary fibrin/fibrinogen degradation products (FDP) measured by highly sensitive ELISA method in various renal diseases].
Shibata T; Sumie A; Ishii T; Tomo T; Magari Y; Sato J; Yasumori R; Nasu M
Nihon Jinzo Gakkai Shi; 1993 Jun; 35(6):687-94. PubMed ID: 8377281
[TBL] [Abstract][Full Text] [Related]
16. Fibrinolysis in glomerulonephritis treated with ancrod: renal functional, immunologic and histopathologic effects.
Kim S; Wadhwa NK; Kant KS; Pollak VE; Glas-Greenwalt P; Weiss MA; Hong CG
Q J Med; 1988 Nov; 69(259):879-905. PubMed ID: 3078212
[TBL] [Abstract][Full Text] [Related]
17. [Long-term effect of dilazep therapy in patients with chronic glomerulonephritis and nephrotic syndrome].
Takasaki H; Shibata M; Ito S; Kida H; Morozumi K; Iwata J
Nihon Jinzo Gakkai Shi; 1987 Jan; 29(1):87-96. PubMed ID: 3586400
[No Abstract] [Full Text] [Related]
18. [The therapeutical effect of dipyridamole on chronic glomerulonephritis and nephrotic syndrome in large dose administration--the study in a double blind group comparison method (author's transl)].
Ishikawa H; Honjo A; Hayashi M; Hamaguchi T; Morita T; Tesutani T; Yamamoto M; Fujimoto Y; Okubo A; Oka G
Nihon Jinzo Gakkai Shi; 1979 Feb; 21(2):135-55. PubMed ID: 381736
[No Abstract] [Full Text] [Related]
19. [Fibrin and fibrinogen degradation products in the urine of patients with nephrotic syndrome].
Ena IaM
Sov Med; 1975 Jul; (7):85-9. PubMed ID: 1216058
[No Abstract] [Full Text] [Related]
20. Plasminogen activator in nephrotic syndrome.
Andreenko GV; Podoroldskaya LV; Polyantseva LP
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(3):351-5. PubMed ID: 2465229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
